Phaseline

Targets › DNMT3A

DNMT3A (DNA): drug programs, companies and trials

7 programs from 6 companies in 260 trials: 146 Phase 2, 98 Phase 1, 11 Phase 3, 5 Phase 4; Oncology, Hematology, Neurology; next expected readout Dec 2026.

DNA (cytosine-5)-methyltransferase that mediates genome-wide de novo methylation and which is essential for the establishment of DNA methylation patterns during development. It modifies DNA in a non-processive manner and methylates both CpG and non-CpG sites. (UniProt, Q9Y6K1)

Open in Phaseline: the race on DNMT3A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
AbbVieAzacitidine
DNA (cytosine-5)-methyltransferase 3A inhibitor; DNA (cytosine-5)-methyltransferase 1 inhibitor
DNMT3A, DNMT1Phase 4Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS)Jul 2027
National Cancer Institute (NCI)Guadecitabine
DNA methyltransferase (DNMT) inhibitor
DNMT1, DNMT3A, DNMT3BPhase 2Locally Advanced Unresectable Primary Central ChondrosarcomaJan 2027
Taiho OncologyAzacitidine (ASTX030)
DNA (cytosine-5)-methyltransferase 3A inhibitor; DNA (cytosine-5)-methyltransferase 1 inhibitor
DNMT3A, DNMT1Phase 2Myelodysplastic SyndromesNov 2027
Bristol-Myers SquibbAzacitidine (BMS-986345)
DNA (cytosine-5)-methyltransferase 3A inhibitor; DNA (cytosine-5)-methyltransferase 1 inhibitor
DNMT3A, DNMT1Phase 2Acute Myeloid Leukemia; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Angioimmunoblastic T-cell Lymphoma (AITL) …Jul 2028
Taiho OncologyDecitabine (ASTX727)
DNA (cytosine-5)-methyltransferase 3A inhibitor; DNA (cytosine-5)-methyltransferase 1 inhibitor
DNMT3A, DNMT1Phase 1Acute Myeloid LeukemiaDec 2026
University of Southern CaliforniaGuadecitabine
DNMT inhibitor
DNMT1, DNMT3A, DNMT3BPhase 1Extrahepatic Bile Duct Adenocarcinoma, Biliary Type; Chronic Myelomonocytic LeukemiaDec 2026
EpiDestinyDecitabine
DNA (cytosine-5)-methyltransferase 3A inhibitor; DNA (cytosine-5)-methyltransferase 1 inhibitor
DNMT3A, DNMT1Phase 1Sickle Cell Disease; Multiple Sclerosis; Allogeneic Hematopoietic Stem Cell Transplantation (HSCT); AML (Acute Myeloid Leukemia) …Oct 2028

Conditions

Acute Myeloid Leukemia (71) Myelodysplastic Syndromes (13) AML (7) Chronic Myelomonocytic Leukemia (6) Leukemia, Myeloid, Acute (5) Acute Myeloid Leukemia (AML) (5) Solid Tumor (5) T-cell Acute Lymphoblastic Leukemia (4) Myeloid Malignancy (4) AML, Adult (4) Sickle Cell Disease (3) Hairy Cell Leukemia (3)

Modalities

small molecule (6), mixed (1)

Companies

Taiho Oncology (2) University of Southern California (1) EpiDestiny (1) AbbVie (1) National Cancer Institute (NCI) (1) Bristol-Myers Squibb (1)

Related targets

DNMT1 (7) DNMT3B (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.